| ID Source | ID |
|---|---|
| PubMed CID | 5329106 |
| CHEMBL ID | 13608 |
| MeSH ID | M0538271 |
| Synonym |
|---|
| 5-{[(3z)-5-fluoro-2-oxo-2,3-dihydro-1h-indol-3-ylidene]methyl}-2,4-dimethyl-n-[2-(pyrrolidin-1-yl)ethyl]-1h-pyrrole-3-carboxamide |
| bdbm4818 |
| HY-10330 |
| palladia |
| toceranib |
| pha-291639 |
| CHEMBL13608 |
| 356068-94-5 |
| D08503 |
| toceranib (usan) |
| 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide |
| 5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-n-[2-(1-pyrrolidinyl)ethyl]-1h-pyrrole-3-carboxamide |
| unii-59l7y0530c |
| 59l7y0530c , |
| toceranib [usan:inn] |
| CS-0241 |
| BCP0726000021 |
| (z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide |
| toceranib [usan] |
| toceranib [inn] |
| 5-[(z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]-2,4-dimethyl-n-[2-(pyrrolidin-1-yl)ethyl]-1h-pyrrole-3-carboxamide |
| 1h-pyrrole-3-carboxamide, 5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(1-pyrrolidinyl)ethyl)- |
| toceranib [mi] |
| toceranib [ema epar veterinary] |
| (z)-5-((5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide |
| (z)-5-(5-fluoro-2-oxo-2,3-dihydro-1h-indol-3-ylidenemethyl)-2,4-dimethyl-n-[2-(1-pyrrolidinyl)ethyl]-1h-pyrrole-3-carboxamide |
| AC-26968 |
| AKOS024457864 |
| DTXSID50189076 , |
| mfcd16038046 |
| NCGC00378902-05 |
| toceranib(su 11654; pha 291639) |
| toceranib free base |
| 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3z)-ylidenemethyl]-2,4-dimethyl-1h-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide |
| 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3z)-ylidenemethyl)-2,4-dimethyl-1h-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide |
| 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3 z)-ylidenemethyl]-2,4-dimethyl-1h-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide |
| SRSGVKWWVXWSJT-ATVHPVEESA-N |
| 5-[5-fluoro-2-oxo-1, 2-dihydro-indol-(3z)-ylidenemethyl)-2,4-dimethyl-1h-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide |
| 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3z)-ylidenemethyl]-2,4-dimethyl-1h-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide |
| 4720B |
| AS-31877 |
| pha 291639esu11654 |
| pha 291639e |
| NCGC00378902-03 |
| compound 12f [pmid: 12646019] |
| palladiar |
| gtpl11619 |
| A874574 |
| toceranibum |
| dtxcid80111567 |
| 5-((z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide |
| toceranib (ema epar veterinary) |
| EN300-7399740 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 10.1531 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 21.3174 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| Interferon beta | Homo sapiens (human) | Potency | 10.1531 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 17.7828 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 10.9900 | 0.0000 | 0.5369 | 10.0000 | AID1795684; AID66610 |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | IC50 (µMol) | 0.0850 | 0.0018 | 0.7552 | 9.5000 | AID157329; AID161264 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 4.7924 | 0.0006 | 0.8007 | 8.5000 | AID161263; AID1795684; AID1795685 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 6.9650 | 0.0002 | 0.9420 | 10.0000 | AID1795684; AID73459 |
| Platelet-derived growth factor receptor alpha | Mus musculus (house mouse) | IC50 (µMol) | 0.0850 | 0.0018 | 0.8572 | 9.5000 | AID157329; AID161264 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 6.0050 | 0.0000 | 0.4830 | 8.8000 | AID1795684; AID216911 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (58.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||